Delcath Systems Inc. (NASDAQ:DCTH) saw its shares rise 2.2% in premarket trading Thursday after new research underscored the potential survival benefits of its liver-targeted treatment for metastatic ...

Researchers explored the effect of adding concurrent local therapy to tebentafusp in patients with metastatic uveal melanoma after progression.

For patients with metastatic uveal melanoma, what are the treatment options? Marlana M. Orloff, M.D.: Metastatic uveal melanoma is unique in that when patients recur, close to 90% or more recur in ...

Delcath Systems, Inc. (Nasdaq: DCTH), ("Delcath" or the "Company") an interventional oncology company focused on the ...

The Phase 2 OptimUM-09 trial shows promising results for uveal melanoma, addressing the lack of approved systemic therapies. Significant tumor size reduction and improved visual acuity were observed ...

Share on Facebook. Opens in a new tab or window Share on Bluesky. Opens in a new tab or window Share on X. Opens in a new tab or window Share on LinkedIn. Opens in a new tab or window So at AAO I gave ...

Marlana M. Orloff, M.D.: Hello, and welcome to CURE®'s Educated Patient Sound Bites on metastatic uveal melanoma. I’m Dr. Marlana Orloff, an associate professor of medicine at Thomas Jefferson ...

The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has recommended granting a marketing authorisation for tebentafusp (Kimmtrak; Immunocore), a novel ...